hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.21860/medflum2019_221600

Diabetes mellitus and DPP IV/CD26 Inhibitors

Lara Batičić ; Zavod za medicinsku kemiju, biokemiju i kliničku kemiju, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Lara Ivanović ; Studentica Medicinskog fakulteta Sveučilišta u Rijeci, Rijeka, Hrvatska
Antonijo Grčić ; Student Medicinskog fakulteta Sveučilišta u Rijeci, Rijeka, Hrvatska
Ester Pernjak Pugel ; Zavod za histologiju i embriologiju, Medicinski fakultet, Sveučilište u Rijeci, Rijeka, Hrvatska
Jadranka Varljen ; Zavod za medicinsku kemiju, biokemiju i kliničku kemiju, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Dijana Detel ; Zavod za medicinsku kemiju, biokemiju i kliničku kemiju, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska

Puni tekst: hrvatski, pdf (1 MB) str. 200-214 preuzimanja: 53* citiraj
APA 6th Edition
Batičić, L., Ivanović, L., Grčić, A., Pernjak Pugel, E., Varljen, J. i Detel, D. (2019). Šećerna bolest i inhibitori DPP IV/CD26. Medicina Fluminensis, 55 (3), 200-214. https://doi.org/10.21860/medflum2019_221600
MLA 8th Edition
Batičić, Lara, et al. "Šećerna bolest i inhibitori DPP IV/CD26." Medicina Fluminensis, vol. 55, br. 3, 2019, str. 200-214. https://doi.org/10.21860/medflum2019_221600. Citirano 20.10.2019.
Chicago 17th Edition
Batičić, Lara, Lara Ivanović, Antonijo Grčić, Ester Pernjak Pugel, Jadranka Varljen i Dijana Detel. "Šećerna bolest i inhibitori DPP IV/CD26." Medicina Fluminensis 55, br. 3 (2019): 200-214. https://doi.org/10.21860/medflum2019_221600
Harvard
Batičić, L., et al. (2019). 'Šećerna bolest i inhibitori DPP IV/CD26', Medicina Fluminensis, 55(3), str. 200-214. https://doi.org/10.21860/medflum2019_221600
Vancouver
Batičić L, Ivanović L, Grčić A, Pernjak Pugel E, Varljen J, Detel D. Šećerna bolest i inhibitori DPP IV/CD26. Medicina Fluminensis [Internet]. 2019 [pristupljeno 20.10.2019.];55(3):200-214. https://doi.org/10.21860/medflum2019_221600
IEEE
L. Batičić, L. Ivanović, A. Grčić, E. Pernjak Pugel, J. Varljen i D. Detel, "Šećerna bolest i inhibitori DPP IV/CD26", Medicina Fluminensis, vol.55, br. 3, str. 200-214, 2019. [Online]. https://doi.org/10.21860/medflum2019_221600

Sažetak
Diabetes (lat. Diabetes mellitus) is a chronic metabolic disease characterized by persistent hyperglycaemia and carbohydrate, fat and protein metabolism disorders. Diabetes could be classified as type 1 or 2, gestational diabetes, and other, less common forms. Due to a prominent increase in the incidence and prevalence of the disease, it represents a significant public-health problem, being between the ten leading causes of mortality in the world. Dipeptidyl peptidase IV, or molecule CD26 (DPP IV / CD26, EC 3.4.14.5), is an ubiquitous multifunctional transmembrane and soluble glycoprotein and serine peptidase, recognized as a crucial factor in maintaining glucose homeostasis, primarily due to the ability to hydrolize incretins. Scientific and clinical studies have shown a high therapeutic potential of DPP IV/CD26 inhibitors in diabetic patients. This review focuses on various aspects of type 1 and 2 diabetes and newer treatment approaches for these diseases, with a special focus on DPP IV/CD26 inhibitors as effective therapeutic options.

Ključne riječi
CD26; Diabetes mellitus; dipeptidyl peptidase IV; DPP IV/CD26 inhibitors

Hrčak ID: 221600

URI
https://hrcak.srce.hr/221600

[hrvatski]

Posjeta: 133 *